Stocks News

LAST PRICE
39.1900
TODAY'S CHANGE (%)
Trending Up0.7300 (1.8981%)

Bid / Lots
39.1900/ 10
Ask / Lots
39.9600/ 5
Open / Previous Close
38.5600 / 38.4600
Day Range
Low 38.5000
High 39.5800
52 Week Range
Low 35.9500
High 54.4446
Volume
1,019,401
average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Nov 7, 2024
- DJ Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo, from 10:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  10:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: IONS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IONS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 10:30 ET (15:30 GMT)
- Ionis to present at upcoming investor conferences, from 7:05AM ET on Thursday Nov 07, 2024 by PR Newswire
  7:05AM ET on Thursday Nov 07, 2024 by PR Newswire
  Companies Mentioned: IONS
  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
  https://mma.prnewswire.com/media/1735807/Ionis.jpg
- Ionis to present at upcoming investor conferences, from 7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
  7:05AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: IONS
  
  Ionis to present at upcoming investor conferences
  
  PR Newswire
  
  CARLSBAD, Calif., Nov. 7, 2024
  
  CARLSBAD, Calif., Nov. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences:
- DJ Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham, from 5:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  5:30AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: IONS
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/IONS/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 07, 2024 05:30 ET (10:30 GMT)
Nov 6, 2024
- Ionis Reports Late-Stage Trial Design in Angelman Syndrome, from 2:29PM ET on Wednesday Nov 06, 2024 by MT Newswires
  2:29PM ET on Wednesday Nov 06, 2024 by MT Newswires
  Companies Mentioned: IONS
  02:29 PM EST, 11/06/2024 (MT Newswires) -- Ionis Pharmaceuticals (IONS) said Wednesday it has aligned with the US Food and Drug Administration on ION582, its investigational medicine for the treatment of people living with Angelman syndrome. "We wil...

Today
- ADMA Biologics, Inc. Is Being Investigated For Defrauding Investors And Those With Losses Are Urged To Reach Out To The Schall Law Firm, from 3 hours ago by Dow Jones
  3 hours ago by Dow Jones
  Companies Mentioned: ADMA
Yesterday
- The Schall Law Firm Invites Stockholders To Help With An Inquiry Into ADMA Biologics Inc's Securities Related Infractions, from 11:04AM ET on Saturday Nov 09, 2024 by Dow Jones
  11:04AM ET on Saturday Nov 09, 2024 by Dow Jones
  Companies Mentioned: ADMA
- Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit, from 10:30AM ET on Saturday Nov 09, 2024 by Dow Jones
  10:30AM ET on Saturday Nov 09, 2024 by Dow Jones
  Companies Mentioned: RARE
- Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation, from 6:00AM ET on Saturday Nov 09, 2024 by Dow Jones
  6:00AM ET on Saturday Nov 09, 2024 by Dow Jones
  Companies Mentioned: ADMA
Nov 8, 2024
- DJ ADMA Biologics Is Maintained at Buy by HC Wainwright & Co., from 2:34PM ET on Friday Nov 08, 2024 by Dow Jones
  2:34PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: ADMA
- DJ ADMA Biologics Is Maintained at Strong Buy by Raymond James, from 12:46PM ET on Friday Nov 08, 2024 by Dow Jones
  12:46PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: ADMA
- ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm, from 10:21AM ET on Friday Nov 08, 2024 by PR Newswire
  10:21AM ET on Friday Nov 08, 2024 by PR Newswire
  Companies Mentioned: ADMA
- ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm, from 10:21AM ET on Friday Nov 08, 2024 by Dow Jones
  10:21AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: ADMA
- ADMA INVESTOR NEWS: ADMA Biologics Investors with Losses May have been Affected by Fraud; Contact BFA Law (Nasdaq:ADMA), from 6:37AM ET on Friday Nov 08, 2024 by Dow Jones
  6:37AM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: ADMA
Nov 7, 2024
- -- Earnings Flash (ADMA) ADMA BIOLOGICS Reports Q3 EPS $0.15, from 4:06PM ET on Thursday Nov 07, 2024 by MT Newswires
  4:06PM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: ADMA

Ionis Pharmaceuticals Inc
NASDAQ:IONSUnited States

Search Criteria

Nov 7, 2024

DJ Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo, from 10:30AM ET on Thursday Nov 07, 2024 by Dow Jones

Ionis to present at upcoming investor conferences, from 7:05AM ET on Thursday Nov 07, 2024 by PR Newswire

Ionis to present at upcoming investor conferences, from 7:05AM ET on Thursday Nov 07, 2024 by Dow Jones

DJ Ionis Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham, from 5:30AM ET on Thursday Nov 07, 2024 by Dow Jones

Nov 6, 2024

Ionis Reports Late-Stage Trial Design in Angelman Syndrome, from 2:29PM ET on Wednesday Nov 06, 2024 by MT Newswires

Peers Headlines

Today

ADMA Biologics, Inc. Is Being Investigated For Defrauding Investors And Those With Losses Are Urged To Reach Out To The Schall Law Firm, from 3 hours ago by Dow Jones

Yesterday

The Schall Law Firm Invites Stockholders To Help With An Inquiry Into ADMA Biologics Inc's Securities Related Infractions, from 11:04AM ET on Saturday Nov 09, 2024 by Dow Jones

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST's 17th Annual Global Science Summit, from 10:30AM ET on Saturday Nov 09, 2024 by Dow Jones

Kirby McInerney LLP Reminds ADMA Biologics, Inc. (ADMA) Investors of Shareholder Investigation, from 6:00AM ET on Saturday Nov 09, 2024 by Dow Jones

Nov 8, 2024

DJ ADMA Biologics Is Maintained at Buy by HC Wainwright & Co., from 2:34PM ET on Friday Nov 08, 2024 by Dow Jones

DJ ADMA Biologics Is Maintained at Strong Buy by Raymond James, from 12:46PM ET on Friday Nov 08, 2024 by Dow Jones

ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm, from 10:21AM ET on Friday Nov 08, 2024 by PR Newswire

ADMA Investors Have Opportunity to Join ADMA Biologics, Inc. Fraud Investigation with the Schall Law Firm, from 10:21AM ET on Friday Nov 08, 2024 by Dow Jones

ADMA INVESTOR NEWS: ADMA Biologics Investors with Losses May have been Affected by Fraud; Contact BFA Law (Nasdaq:ADMA), from 6:37AM ET on Friday Nov 08, 2024 by Dow Jones

Nov 7, 2024

-- Earnings Flash (ADMA) ADMA BIOLOGICS Reports Q3 EPS $0.15, from 4:06PM ET on Thursday Nov 07, 2024 by MT Newswires